• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org

CNETS India informs Alpha PRRT is now available for NET patients in India

CNETS India
CNETS India informs Alpha PRRT is now available for NET patients in India

CNETS India team is happy to share that two nuclear medicine centres in India have started Alpha PRRT for NET patients.  World over, many clinical trials have established the benefit of PRRT for metastatic NETs. Alpha PRRT uses the more powerful alpha particle emitting agents, Actinium 225 or Bismuth 213, in place of Lutetium 177 or Yttrium 90, which are the commonly used beta emitters for PRRT, to target the somatostatin receptors expressed by the tumor cells. According to CNETS India, Alpha PRRT holds higher energy leading to higher efficacy and lower toxicity to normal tissues and hence lesser side effects as compared to the currently available Lu177 based PRRT. Currently Alpha PRRT is already available at two superspecialty hospitals in Delhi and Bengaluru in North and South India, respectively.

More information from CNETS India

Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button